ATR earnings analysis
What we found in ATR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
AptarGroup reported strong Q1 2026 earnings with a revenue of $982.9 million, surpassing estimates of $957.6 million, and an adjusted EPS of $1.19, exceeding expectations of $1.15. However, net income saw an 8% decline to $72.7 million compared to last year due to increased costs and a challenging product mix, particularly in the Pharma segment which faced lower sales of higher-margin products. The company anticipates Q2 EPS guidance between $1.32 and $1.40, reflecting a robust growth outlook despite headwinds from supply chain uncertainties.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Exceeds Estimates
- Revenue increased 11% YoY to $982.9 million, surpassing estimates by 2.6%.
- EPS Beat Expectations
- Diluted EPS rose to $1.19, beating the estimated EPS of $1.15 by 3.5%.
- Strong Performance in Beauty Segment
- Beauty segment revenue grew 19% YoY to $363.6 million, aided by strong demand.
- Operating Cash Flow Improvement
- Net cash provided by operations increased to $118.7 million from $82.7 million YoY.
- Free Cash Flow Nearly Doubled
- Free cash flow rose to $53.3 million from $25.9 million in the previous period.
- Q2 EPS Guidance Provided
- Management expects Q2 EPS to be in the range of $1.32 to $1.40.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Costs in Pharma Segment
- Pharma operating income margin fell to 33.3%, down from 34.8% due to lower sales of higher-margin products.
- Interest Expense Rise
- Interest expense increased to $16.9 million, up from $11.4 million Year-over-Year.
- Potential Supply Chain Disruptions
- Uncertainties from geopolitical conditions could negatively impact operations and margins.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.19
- Gross margin
- 35.8%
- Operating margin
- 10.9%
- Segment
- Pharma
- Segment
- Beauty
- Segment
- Closures
What they said about what is next.
EPS guidance for Q2 2026 provided as $1.32 to $1.40, reflecting positive outlook.
The filing reads better than the one before it.
What came before.
- 10-Q · October 31, 2025
- AptarGroup reported Q3 net sales of $961,131,000 and diluted EPS of $1.92 for the three months ended September 30, 2025, with net income attributable to AptarGroup of $127,927,000 (up from $100,039,000 a year earlier).…
- 10-Q · May 2, 2025
- Aptar reported Q1 2025 net sales of $887.3M, down $28.1M (-3.1%) versus Q1 2024, while operating income ticked up to $113.4M (+$1.4M). Gross margin remained near 37.9% and diluted EPS was $1.17 (down from $1.23).…
- 10-Q · July 26, 2024
- Aptar reported Q2 net sales of $910,063,000 and diluted EPS of $1.34 for the three months ended June 30, 2024. Revenue was up modestly versus Q2 2023 (+$14,157,000) while gross margin expanded to ~37.7% and operating…
- 10-Q · April 28, 2023
- Aptar reported Q1 net sales of $860,067,000, up $15,135,000 (+1.8%) versus Q1 2022, while diluted EPS fell to $0.82 from $0.93 a year ago. Gross profit was $302,645,000 (≈35.2% gross margin) and operating income…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ATR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever